News
Inhibitor may overcome ibrutinib resistance in MCL
The inhibitor, IACS-010759, decreased tumor growth and prolonged survival in mouse models of ibrutinib-resistant lymphoma.
Video
Researchers propose new risk groups for NK-AML
NEWPORT BEACH, CALIF. – Investigators used machine learning algorithms to risk stratify patients with normal karyotype acute myeloid leukemia.
News
Gabapentin falls short in treating sickle cell pain
NEW ORLEANS – Gabapentin plus standard therapy produced results similar to those of placebo plus standard therapy.
News
Researchers win Stand Up To Cancer grants
Five teams received funding for research into leukemia and lung, colon, pancreatic, breast, and ovarian cancers.
Video
Combo proves most effective in HMA-naive, higher-risk MDS
NEWPORT BEACH, CALIF. – Oral rigosertib plus azacitidine produced a 90% response rate in higher-risk patients with myelodysplastic syndromes who...
Video
More abnormal cells linked to poorer ASCT outcomes in MDS
NEWPORT BEACH, CALIF. – Patients with more than 60% cytogenetically abnormal cells at transplant had inferior overall survival and relapse-free...
News
LentiGlobin reduces transfusion dependence in young thalassemia patients
NEW ORLEANS – Children and young adults with non-beta0/beta0 thalassemia achieved transfusion independence in two trials.
Video
Biomarker testing may transform treatment of acute GVHD
NEWPORT BEACH, CALIF. – Testing patient blood samples for two biomarkers may help guide early treatment of acute GVHD.
News
Tagraxofusp produces high response rate in BPDCN
The overall response rate was 90% in previously untreated patients who received the highest dose.
Video
Model inspired by Netflix, Amazon may help guide MDS treatment
NEWPORT BEACH, CALIF. – The researchers used an algorithm to help predict response or resistance to lenalidomide with a high degree of accuracy....
News
Researchers to be honored at ASPHO
Hematology and oncology researchers will receive awards at the 2019 American Society of Pediatric Hematology/Oncology conference.
Video
Sorafenib plus GCLAM held safe in AML, MDS phase-1 study
NEWPORT BEACH, CALIF. – Sorafenib plus GCLAM has shown promise in a phase 1 trial of patients with AML and MDS.
Video
Study highlights lack of data on transgender leukemia patients
NEWPORT BEACH, CALIF. – Researchers identified transgender leukemia patients by detecting gender-karyotype mismatches.
Video
ALF 2019 showcases evolving treatment of AML
NEWPORT BEACH, CALIF. – Dr. Martin Tallman discusses meeting presentations on the treatment of AML.
Video
Back to the drawing board for MPN combo
NEWPORT BEACH, CALIF. – Ruxolitinib plus decitabine won’t proceed to a phase 3 trial for the treatment of accelerated or blast phase...